{"id":"W2406500056","doi":"10.1158/1538-7445.sabcs15-pd5-04","title":"Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Neratinib; Trastuzumab; Medicine; Pertuzumab; Internal medicine; Breast cancer; Regimen; Docetaxel; Oncology; Neoadjuvant therapy; Lapatinib; Metastatic breast cancer; Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005031714,0.001084854,0.002719004,0.0005504817,0.0008542574,0.0003411309,0.0004444252,0.000325683,0.00203945],"category_scores_gemma":[0.0006998192,0.0005172343,0.0001016119,0.001653615,0.002638541,0.0007809653,0.0001789867,0.001844742,0.000005467684],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.003961006,"about_ca_system_score_gemma":0.01302656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005828178,"about_ca_topic_score_gemma":0.008493086,"domain_scores_codex":[0.989296,0.001697515,0.00130503,0.002134354,0.003113139,0.002454029],"domain_scores_gemma":[0.9928724,0.002939165,0.0003916073,0.0008108276,0.001741447,0.001244512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7292787,0.00101417,0.0002536103,0.0001691696,0.0006774916,0.0006888091,0.008854296,0.00006385602,0.06474862,0.000008347954,0.000824506,0.1934184],"study_design_scores_gemma":[0.895781,0.07384039,0.001562235,0.005854276,0.0001148223,0.0003212853,0.005978601,0.0004042253,0.0145032,0.00001584646,0.0006523374,0.0009717357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692052,0.004056901,0.0002199633,0.01044578,0.0001008272,0.01475828,0.000818292,0.00009225184,0.0003024912],"genre_scores_gemma":[0.97172,0.00634518,0.0009051021,0.0006969451,0.0003637055,0.01583498,0.00003438325,0.0002807568,0.003818929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1924467,"threshold_uncertainty_score":0.9998626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05068744065344186,"score_gpt":0.424429407720223,"score_spread":0.3737419670667811,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}